Evidence map›Paper›PMID 32564332›Full record

ArticleJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology2021

Combined 1-Deoxynojirimycin and Ibuprofen Treatment Decreases Microglial Activation, Phagocytosis and Dopaminergic Degeneration in MPTP-Treated Mice.

Tcs Costa, E Fernandez-Villalba, V Izura, A M Lucas-Ochoa, N J Menezes-Filho, R C Santana, M D de Oliveira, F M Araújo, C Estrada, Vda Silva and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 42 citations in OpenAlex.

  1. Neuroprotection in Parkinson Disease.Neurology and therapy · 2025
    Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Tcs CostaClinical & Experimental Neuroscience (NiCE). Institute for Bio-Health Research of Murcia (IMIB), Institute for Aging Research (IUIE). School of Medicine, University of Murcia, Murcia, Spain.
E Fernandez-VillalbaClinical & Experimental Neuroscience (NiCE). Institute for Bio-Health Research of Murcia (IMIB), Institute for Aging Research (IUIE). School of Medicine, University of Murcia, Murcia, Spain.
V IzuraClinical & Experimental Neuroscience (NiCE). Institute for Bio-Health Research of Murcia (IMIB), Institute for Aging Research (IUIE). School of Medicine, University of Murcia, Murcia, Spain.
A M Lucas-OchoaClinical & Experimental Neuroscience (NiCE). Institute for Bio-Health Research of Murcia (IMIB), Institute for Aging Research (IUIE). School of Medicine, University of Murcia, Murcia, Spain.
N J Menezes-FilhoDepartment of Biochemistry and Biophysics, Laboratory of Neurochemistry and Cell Biology, Institute of Health Sciences, Federal University of Bahia, Salvador, Bahia, 40110-100, Brazil.
R C SantanaDepartment of Bioregulation, Laboratory of Neuroscience, Institute of Health Sciences, Federal University of Bahia, Salvador, Bahia, 40110-100, Brazil.
M D de OliveiraDepartment of Biochemistry and Biophysics, Laboratory of Neurochemistry and Cell Biology, Institute of Health Sciences, Federal University of Bahia, Salvador, Bahia, 40110-100, Brazil.
F M AraújoClinical & Experimental Neuroscience (NiCE). Institute for Bio-Health Research of Murcia (IMIB), Institute for Aging Research (IUIE). School of Medicine, University of Murcia, Murcia, Spain.
C EstradaClinical & Experimental Neuroscience (NiCE). Institute for Bio-Health Research of Murcia (IMIB), Institute for Aging Research (IUIE). School of Medicine, University of Murcia, Murcia, Spain.
Vda SilvaDepartment of Biochemistry and Biophysics, Laboratory of Neurochemistry and Cell Biology, Institute of Health Sciences, Federal University of Bahia, Salvador, Bahia, 40110-100, Brazil.
S L CostaDepartment of Biochemistry and Biophysics, Laboratory of Neurochemistry and Cell Biology, Institute of Health Sciences, Federal University of Bahia, Salvador, Bahia, 40110-100, Brazil. costasl@ufba.br.ORCID 0000-0002-8975-3871
M T HerreroClinical & Experimental Neuroscience (NiCE). Institute for Bio-Health Research of Murcia (IMIB), Institute for Aging Research (IUIE). School of Medicine, University of Murcia, Murcia, Spain. mtherrer@um.es.
Universidade Federal da Bahia · BRUniversidad de Murcia · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammation is a predominant aspect of neurodegenerative diseases and experimental studies performed in animal models of Parkinson's disease (PD) suggesting that a sustained neuroinflammation exacerbates the nigrostriatal degeneration pathway. The central role of microglia in neuroinflammation has been studied as a target for potential neuroprotective drugs for PD, for example nonsteroidal anti-inflammatory drugs (NSAIDs) and matrix metalloproteinases (MMP) inhibitors that regulates microglial activation and migration. The aim of this study was to investigate the neuroprotective response of the iminosugar 1-deoxynojirimycin (1-DNJ) and compare its effect with a combined treatment with ibuprofen. MPTP-treated mice were orally dosed with ibuprofen and/or 1-DNJ 1. Open-field test was used to evaluate behavioral changes. Immunohistochemistry for dopaminergic neurons marker (TH

Indexed as

1-DeoxynojirimycinAnimalsAnti-Inflammatory AgentsBehavior, AnimalDopaminergic NeuronsEnzyme InhibitorsIbuprofenMaleMiceMice, Inbred C57BLMicrogliaNerve DegenerationNeuroprotective AgentsParkinsonian DisordersPhagocytosis1-DeoxynojirimycinAnti-Inflammatory AgentsEnzyme InhibitorsIbuprofenNeuroprotective AgentsMicrogliosisNeurodegenerationNeuroinflammationParkinson’s diseasePhagocytosis

Identifiers

PMID32564332
OpenAlexW3035974263

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.